Selective vasopressin V1A receptor antagonist. Inhibits vasopressin and oxytocin-induced increases in intracellular calcium concentrations in vitro (IC50 values are 5 and 30 nM respectively). Exhibits potent and prolonged antivasopressor activity and induces anxiolytic-like effects in the dorsal, but not ventral, hippocampus in vivo.
(Modifications: Tyr-1 = Pmp-Tyr(Me), Gly-8 = C-terminal amide)
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 2 mg/ml in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 1151.38. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.87 mL||4.34 mL||8.69 mL|
|5 mM||0.17 mL||0.87 mL||1.74 mL|
|10 mM||0.09 mL||0.43 mL||0.87 mL|
|50 mM||0.02 mL||0.09 mL||0.17 mL|
References are publications that support the biological activity of the product.
Kruszynski et al (1980) [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vas J.Med.Chem. 23 364 PMID: 6892930
Spath et al (1996) Arginine vasopressin and oxytocin increase intracellular calcium and cAMP in human glomerular epithelial cells in culture. Kidney Blood Press.Res. 19 81 PMID: 8871886
Tsuchiya et al (2002) Vasopressin inhibits sarcolemmal ATP-sensitive K+ channels via V1 receptors activation in the guinea pig heart. Circ.J. 66 277 PMID: 11922278
Engin and Treit (2008) Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus. Neuropeptides 42 411 PMID: 18508119
If you know of a relevant reference for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin, please let us know.
View Related Products by Product Action
Keywords: (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin, (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin supplier, Selective, vasopressin, V1A, antagonists, V2, Receptors, Vasopressin, 3377, Tocris Bioscience
Citations for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
Citations are publications that use Tocris products.
Currently there are no citations for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin. Do you know of a great paper that uses (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin from Tocris? Please let us know.
Reviews for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
There are currently no reviews for this product. Be the first to review (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin and earn rewards!
Have you used (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.